MicroRNA Analysis in Epithelial Ovarian Cancer

Czech version

Authors: L. Sommerová; H. Ďuríková; J. Podhorec; R. Hrstka
Authors‘ workplace: RECAMO, Masarykův onkologický ústav, Brno
Published in: Klin Onkol 2017; 30(Supplementum1): 180-183
Category: Article

Overview

Background:
Ovarian carcinoma is a type of cancer with high mortality, which is often diagnosed in late stages indicating the necessity to identify new non-invasive biomarkers for detection this malignancy in early stages of the disease. MicroRNAs (miRNAs) seem to be one of the potential possibilities. MiRNAs are small noncoding RNA molecules, which regulate gene expression and are involved in many cellular processes including carcinogenesis.

Patients and Methods:
Total RNA was isolated from sera of nine ovarian cancer patients treated at Masaryk Memorial Cancer Institute. As a control samples, we used sera from six cancer-free women. Purified RNA was subjected to reverse transcription followed by cDNA preamplification. MiRNA expression was determined using TaqMan MicroRNA Assays. For statistical analysis was used nonparametric Mann-Whitney U test.

Results:
MiRNAs miR-30a-5p and miR-26b were identified as significantly overexpressed miRNAs in sera from ovarian cancer patients. Other miRNAs showing elevated level were identified as miR-628-5p, 520c-3p, miR-486 and let-7b. On the other hand, miR-596 showed reduced levels in sera from ovarian cancer patients.

Conclusion:
A significantly different level of at least two miRNAs (miR-30a-5p a miR-26b) has been observed in cancer patients in comparison with healthy individuals. These miRNAs would serve as a powerful non-invasive diagnostic tool to detect ovarian epithelial cancer in so called liquid biopsies.

Key words:
microRNA – biomarkers – ovarian epithelial cancer – qPCR

This work was supported by MEYS – NPS I – LO1413.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
13. 3. 2017

Accepted:
26. 3. 2017

Sources

1. Trivers KF, Stewart SL, Peipins L et al. Expanding the public health research agenda for ovarian cancer. J Womens Health (Larchmt) 2009; 18 (9): 1299–1305. doi: 10.1089/jwh.2009.1622.

2. Ahmad J, Hasnain SE, Siddiqui MA et al. MicroRNA in carcinogenesis & cancer diagnostics: a new paradigm. Indian J Med Res 2013; 137 (4): 680–694.

3. Matoulkova E, Michalova E, Vojtesek B et al. The role of the 3’ untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol 2012; 9 (5): 563–576. doi: 10.4161/rna.20231.

4. Michalova E, Vojtesek B, Hrstka R. Impaired pre-mRNA processing and altered architecture of 3’ untranslated regions contribute to the development of human disorders. Int J Mol Sci 2013; 14 (8): 15681–15694. doi: 10.3390/ijms140815681.

5. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11 (4): 441–450.

6. Endo H, Muramatsu T, Furuta M et al. Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis 2013; 34 (3): 560–569. doi: 10.1093/carcin/bgs376.

7. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67 (18): 8699–8707.

8. Wu J, Wei JJ. HMGA2 and high-grade serous ovarian carcinoma. J Mol Med (Berl) 2013; 91 (10): 1155–1165. doi: 10.1007/s00109-013-1055-8.

9. Han X, Zhen S, Ye Z et al. A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells. Cell Physiol Biochem 2017; 41 (3): 973–986. doi: 10.1159/000460 618.

10. Liu J, Wu X, Liu H et al. Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines. Oncol Lett 2016; 12 (3): 2065–2070.

11. Sander S, Bullinger L, Wirth T. Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle 2009; 8 (4): 556–559.

12. Lin J, Zhang L, Huang H et al. MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4. Oncotarget 2015; 6 (27): 23793–23806.

13. Zhang L, Volinia S, Bonome T et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008; 105 (19): 7004–7009. doi: 10.1073/pnas.0801615 105.